CME QUESTIONS FOR JUNE 2003 ISSUE OF THE JOURNAL OF UROLOGY

CME QUESTIONS FOR JUNE 2003 ISSUE OF THE JOURNAL OF UROLOGY 1. LABORATORY EVALUATIONS OF ERECTILE DYSFUNCTION: AN EVIDENCE BASED APPROACH (vol. 169, pp. 2262–2264) The following laboratory test is not warranted for screening men presenting with erectile dysfunction: a) b) c) d) e)

testosterone prolactin cholesterol glycosylated hemoglobin thyroid stimulating hormone

2. A LONGITUDINAL ASSESSMENT OF BOWEL RELATED SYMPTOMS AND FECAL INCONTINENCE FOLLOWING RADICAL PERINEAL PROSTATECTOMY (vol. 169, pp. 2220 –2224) Following radical perineal prostatectomy: a) b) c) d) e)

preoperative rectal urgency improves preoperative involuntary stool leakage improves the incidence of involuntary stool leakage is 2.9% at 12 months quality of life issues related to bowel function rarely improve rectal urgency rarely occurs

3. PERCENT OF PROSTATE NEEDLE BIOPSY CORES WITH CANCER IS A SIGNIFICANT INDEPENDENT PREDICTOR OF PROSTATE SPECIFIC ANTIGEN RECURRENCE FOLLOWING RADICAL PROSTATECTOMY: RESULTS FROM THE SEARCH DATABASE (vol. 169, pp. 2136 –2141) The percent of positive prostate needle biopsy cores in patients with carcinoma who undergo radical prostatectomy: a) b) c) d) e)

is a predictor of adverse pathological findings cannot predict biochemical failure cannot be used to stratify patient risk level preoperatively is more important than percent positive from 1 side compared to the other has no predictive value of any type

4. IS THERE AN OPTIMAL TIMING FOR INTRACAVERNOUS PROSTAGLANDIN E1 REHABILITATION FOLLOWING NONNERVE SPARING RADICAL PROSTATECTOMY? RESULTS FROM A HEMODYNAMIC PROSPECTIVE STUDY (vol. 169, pp. 2166 –2169) The use of intracavernosal prostaglandin E1 injection therapy following nonnerve sparing radical prostatectomy: a) b) c) d) e)

will not produce a functional erection works best if begun within the first 3 postoperative months works best if begun after 4 postoperative months works best if begun after 6 postoperative months works best if begun after 12 postoperative months

5. RANDOMIZED CONTROLLED TRIAL OF ZOLEDRONIC ACID TO PREVENT BONE LOSS IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NONMETASTATIC PROSTATE CANCER (vol. 169, pp. 2008 –2012) In men receiving androgen deprivation therapy for nonmetastatic prostate cancer treatment with the bisphosphonate zoledronic acid: a) b) c) d) e)

increases the duration of response prevents bone metastases increases bone mineral density activates osteoclasts is poorly tolerated

2349